Original Article

Silibinin suppresses CD44 expression in prostate cancer cells

Alina M. Handorean1, Kui Yang1, Eric W. Robbins1, Thomas W. Flaig2, Kenneth A. Iczkowski1

1From the Department of Pathology, University of Colorado Health Science Center, Aurora, Colorado; 2From the Department of Medicine, Division of Urologic Oncology, University of Colorado Health Science Center, Aurora, Colorado.

Received December 20, 2008; accepted December 30, 2008; available online January 1, 2009

Abstract: Prostate cancer (PCa), like most human cancers, features dysregulated CD44 expression. Expression of CD44 standard (CD44s), present in benign epithelium, is lost in PCa while pro-invasive splice variant isoform CD44v7-10 is overexpressed. The role of CD44 in silibinin’s anti-growth effects was uncertain. To assess silibinin’s effects on CD44 promoter activity, PC-3M PCa cells were transfected with luciferase-CD44 promoter construct 24 h prior to 25-200 µM silibinin treatment for 48 h. Also, cells’ expression of CD44 RNA (by qRT-PCR) and protein (Western blot analysis) was studied. Silibinin was further tested preoperatively on a pilot cohort of 6 men with PCa compared with 7 matched placebo-treated men, with immunostaining for CD44v7-10 in their prostates. In PC-3M cells, silibinin dose-dependently inhibited CD44 promoter activity up to 87%, caused a 90% inhibition of total CD44 and 70% decrease in CD44v7-10 RNA, and at the protein level, decreased total CD44 at 100-200 µM dose and decreased CD44v7-10 after 3 days. Silibinin decreased adhesion to hyaluronan and fibronectin. Silibinin at 100-200 µM inhibited Egr-1, a regulator of CD44 promoter activity. Men treated with silibinin did not differ in tissue CD44v7-10 expression. In conclusion, CD44 inhibition is one mechanism by which silibinin reduces PCa tumorigenicity.

Key Words: Silibinin, prostatic neoplasms; CD44; plasmid; alternate splicing; adhesion

Introduction

About 30% of prostate cancer (PCa) cases undergo transition from quiescent to aggressive, and this transition relies on altered expression of adhesion glycoproteins such as CD44 that allow tumor cells to detach, interact with proteins that digest stromal matrix, migrate through matrix and intravasate into lymphovascular channels. CD44 enables cell-cell and cell-matrix adhesion, primarily to hyaluronan but also to other ligands, and links the cell membrane to the actin cytoskeleton, modulating motility. CD44 is a transmembrane molecule encoded by an alternately spliced gene. It is expressed as ubiquitous, standard (CD44s) isoform but inclusion of one or more of 10 variant (v) exons produces tissue-specific (CD44v) isoforms. Moreover, a unique variant isoform of CD44 is overexpressed in PCa and facilitates PCa cell growth and invasion [1-6].

Silibinin is a nutritional supplement that has gained attention as intervention to prevent or treat cancer. Silibinin is a polyphenolic flavonolignan isolated from milk thistle and artichoke that arrests PCa proliferation in vitro [7] with cell cycle arrest in G1 [8], potentiates a chemotherapeutic drugs [9], and in vivo increases apoptosis and inhibits angiogenesis [10]. It inhibits cancer invasion by inactivating the PI3K-Akt and MAPK signaling pathways [11] as well as decreasing production of urokinase-plasminogen activator (uPA) and matrix metalloprotease-2 [12]. The early growth response-1 (Egr-1) transcription factor binds to and activates CD44 promoter [13]. Here we investigate these effects of silibinin on CD44 total and variant, adhesion, and Egr-1 expression.
Silibinin suppresses CD44 expression

Materials and Methods

Cell lines and treatment

PC-3M cells, a metastasis-derived variant of PC-3, were obtained from Dr. Girish Shah, U. of Louisiana—Monroe. LNCaP and DU145 cells were from ATCC (Manassas, VA). Cells were grown in RPMI 1640 (Invitrogen) with 10% fetal calf serum and antibiotics. Cells were grown in 5% CO2 incubator at 37ºC. For each experiment, cells in a flask were trypsinized, washed with sterile PBS to remove trypsin, resuspended in basal medium, and counted after dilution with Trypan blue dye using the grid method.

Cells were treated with a dose of 25 up to 200 µM silibinin; based on the fact that 100 µM most effectively inhibited invasion, MMP-2, and uPA [11,12]. Vehicle for both agents was DMSO, which was applied to control cells.

CD44 promoter luciferase assays

Using the PXP2 plasmid, 1150 bases of CD44 sequence including the start site, and beginning 964 bases upstream to the start site, was cloned in between Xho I and Hind III sites. The efficacy of the promoter construct had been validated based on its inhibition by HOXC6 [14]. Luciferase activity was measured 48 h after transfection using the firefly luciferase assay (Gold Biotechnologies, St. Louis, MO). The cells were harvested in 20 mM K2HPO4 pH 7.8 with 5 mM MgCl2 and 0.5% Triton X-100 buffer for 15 min on ice, and the mixture was centrifuged for 10 min at 4°C. 50 µl of lysate were added to 350 µl of luciferase assay buffer as per the manufacturer. The relative luciferase units (RLU) were normalized to protein concentration as determined by Bradford assay.

Real time TaqMan RNA analysis

Total RNA was prepared from cell pellets using Trizol (Invitrogen, Carlsbad, CA) as described by the manufacturer. RNA was further purified by isopropanol precipitation, resuspended in RNase-free water, and its concentration measured. Complementary DNA (cDNA) was synthesized from 4 µg total RNA in 20 µl reaction mixture as we did previously [15]. At least triplicate samples were run using a primer set that brackets the entire variant region with a probe for CD44v9 [15], primers for CD44 total with a probe that binds a standard exon, and 18S ribosomal RNA. Quantitative PCR reactions were optimized to 4 µg cDNA (0.16 µg with 18S) plus the manufacturer’s master mix and primer/probe sets (Applied Biosystems, Foster City, CA) in a volume of 20 µl. The amplification protocol was as follows: hold 50°C 2 min, 95°C 10 min, then 40 cycles of (95°C for 0:15 and 60°C for 1:00) using the ABI 7500 cycler (Perkin-Elmer, Waltham, MA). Primer/probe sets for CD44v were: forward, AACGCTTCAGCCTACTGCAAA; reverse, TCTTCCAAGCCTTCATGTGATG; probe, GATTTGGACAGGACAGGACCTCTTTCAATG. For CD44 total we used forward, CAACTCCATCTGTGCAGCAAA; reverse, GTAACCTCCTGCTGCTGCTC; probe, CATATTGCTTCAATGCTTCAGCTCCACCTG. Primer and probe sets for 18S were proprietary to the manufacturer.

Western blot analysis

Cultured cells were directly lysed in their wells using RIPA buffer (Upstate Biologicals, Lake Placid, NY) plus the protease inhibitor mini tablets (Roche, Indianapolis, IN). Protein concentration of the cell lysate was estimated by Bradford method. SDS-PAGE was performed on 25 µg sample/lane according to Laemmli method using the NuPAGE system (Invitrogen, Carlsbad, CA). 10 µl of Kaleido-
Silibinin suppresses CD44 expression

Figure 2. qRT-PCR demonstrates mean CD44 RNA levels after 25-100 µM silibinin treatment, normalized to untreated cells. Total CD44 was 91-99% inhibited. CD44v7-10 was 2.4x control value after 25 µM dose but inhibited at higher doses.

scope Precision Plus Protein Standards (Bio-Rad) was run in at least one lane. After electrophoresis for 2 hr, the protein was transferred to nitrocellulose. Primary antibodies were used. Polyclonal anti-Egr-1 C-terminus (Santa Cruz) was used at 1:200. To assess the overexpressed CD44v7-10 the membrane was reacted with neat supernatant from the hybridoma cell line HB-258 (ATCC). CD44 total (standard + variant) was assessed using monoclonal antibody 156-3C11 (Cell Signaling Technology, Danvers, MA) at 1:1000. Anti-β-actin-HRP antibody (Sigma, St. Louis) was used at a dilution of 1:10,000. Membranes were washed 3 x 15 min in TBS with 0.1% Tween 20% and 1:2000 dilution of goat anti-mouse IgG antibody labeled with HRP (Bio-Rad, Hercules, CA) was added in TBS + 5% skim milk for 1 hr. Reactivity was detected using the SuperSignal West Pico Substrate chemiluminescent system (Pierce Biotechnology, Rockford, IL). Each experimental run was conducted at least twice.

Cell adhesion assays

Cellular adhesion assays as described [15], were carried out using trypsinized confluent untreated, PC-3M cells after 48 hour 100 µM silibinin treatment or vehicle only. Each test condition was set in 8 wells. 96-well black-edged, clear flat bottom Costar plates (Cole-Parmer, Vernon Hills, IL) were coated with 20 µg/ml fibronectin (Becton Dickinson, Bedford, MA) or 2 mg/ml hyaluronan (Sigma, St. Louis, MO) [15] at 37°C overnight. To measure baseline nonspecific binding, other wells were coated with 1 mg/ml BSA. 1x10^6 cells suspended in 1 ml PBS were incubated with the dye BCECF-AM (Dojindo, Tokyo) for 15 minutes at 37°C [16]. After two washes of the cells with PBS, cells were added to plates at a density of 3x10^4 per well and incubated at 37°C for 90 min. Fluorescence intensities at 530 nm were measured using a Bio-Tek FL-600 fluorescent plate reader. Nonadherent cells were removed with successive PBS washes, reading fluorescence intensities with PBS in the wells after each. Adhesion was calculated [15] as % cells bound=(100) fluorescence intensity after second wash / fluorescence intensity of total cells plated. The assay was repeated twice.

Immunostaining for CD44v9 in prostate cancer patients

Under written informed consent, six men planning to undergo radical prostatectomy received 13 g silibinin-phytosome daily in 3 divided doses for a 2-4 week duration, and 7 men were untreated controls. Plasma levels of silibinin peaked at 25-150 µM with a half-life ranging from 2-5 hours [17]. The primary antibody was neat supernatant from the hybridoma cell line HB-258 (ATCC) secreting mouse anti-human antibody to CD44v9. The secondary antibody was goat anti-mouse IgG antibody labeled with HRP (Bio-Rad, Hercules, CA).

Statistical analysis

CD44 promoter activity data were analyzed by ANOVA and post t-test, comparing activity at various doses. TaqMan data were analyzed by the 2(ΔΔCt) method [18] to determine fold change in gene expression (untreated cells=1.00). The ΔCt was taken as the difference between the CD44v or CD44 total and the 18S ribosomal RNA CTs. The ΔΔCt was obtained using the mean ΔCt of untreated cells as calibrator. Each TaqMan result was compared to 1.00 using 2-tailed paired t-test. Statistical significance was set at p <0.05. Adhesion assay data are expressed as mean ±SD. The significance of differences among group means was tested by 2-tailed paired t-test.
Results

Silibinin suppresses CD44 promoter activity, RNA and protein.

Transfection of our CD44 promoter construct into PC-3M prostate cancer cells for 24 h was followed by silibinin treatment for 48 h to assess the effects of these agents. Silibinin significantly dose-dependently inhibited promoter activity, up to 86.7% (p<0.001) at 200 µM (Figure 1). Doses from 25 µM to 200 µM differed significantly from no treatment; and a dose of 200 µM caused significantly less promoter activity than all lower doses. Mean RNA levels after all doses of silibinin treatment, normalized to untreated cells, were more than 90% lower for total CD44. CD44v7-10 was noted to be increased only at 200 µM dose. Below: β-actin is shown as a normalizer.

Adhesion assays

Compared to untreated cells, PC-3M cells after 100 µM silibinin had a 66% reduction in rate of adhesion to hyaluronan and 47% reduction in adhesion to fibronectin (Figure 4).

Clinical treatment with silibinin

Prostate tissues from 6 men with prostate cancer treated with silibinin and 7 treated with placebo were immunostained for the functionally important CD44 v7-10 using anti-CD44v9, directed against the largest portion of the included protein product CD44v7-10. Immunoreactivity was scored on a scale of 0-3+. The mean reactivity in treated and untreated men respectively were 1.0 and 1.3 for cancer, 2.9 and 2.6 for benign basal cells, 0.7 and 0.8 for benign secretory cells, and 0.8 and 0.7 for atrophic glands (p=NS). No significant differences were noted.

Candidate mediators of silibinin effect

Silibinin dose of 100 or 200 µM inhibited Egr-1 expression (Figure 5). Bands were observed at 55 kD consistent with the theoretical monomeric form of Egr-1, with dimeric form bands near 110 kD [19]. 100 µM concentration equals the plasma level attained in patients [17]. As a negative control, slow growing, androgen-sensitive LNCaP cells were negative, while more aggressive DU145 cells expressed Egr-1. Immunoblots against EGFR and phospho-EGFR disclosed some silibinin effect (data not shown).

Discussion

We discovered that the nutrient silibinin reduces CD44 promoter activity, resulting in decreased total CD44 RNA. Inhibition of CD44v7-10 was less marked; however, at the protein level, this inhibition was strongly evident after 3 days of treatment. Our interest in CD44v7-10 variant isoform expression in PCa extends back several years. By isolating RNA from clinical PCa specimens, we found CD44v7-10 to be a unique PCa signature,
Silibinin suppresses CD44 expression

Figure 4. Adhesion assay with PC-3M cells after 100 µM silibinin treatment. Adhesion to both hyaluronan and fibronectin is diminished to baseline level, near that of BSA-coated wells, after silibinin treatment.

CD44's adhesive affinities depend on its ability to cluster and multimerize, which is altered by a change in CD44s to CD44 variant ratio. Thus we tested PCA cell adhesion to hyaluronan and fibronectin, two ligands that are most functionally important for CD44 in PCA cells. Binding to these two ligands was most strongly altered in PCA cells compared to benign BPH-1 cells [20], which bound hyaluronan strongly and fibronectin minimally. The androgen-sensitive LNCaP cells bound both ligands equally, while PC-3 and their derivatives bound most strongly to fibronectin, probably representing an integrin-independent mechanism of binding to fibronectin. Moreover, re-expression of CD44s significantly increased adhesion to hyaluronan and decreased adhesion to fibronectin. Here, we observed a loss of total CD44 (which is largely CD44s) after silibinin treatment, consistent with our decreased hyaluronan binding, and lower CD44v7-10 which would mediate less fibronectin binding. Because of the decreased hyaluronan binding, silibinin does not strictly cause reversion to the benign phenotype but is consistent with the decreased migration [7], invasion [11,12] and possibly decreased in vivo growth [8] of cancer cells after silibinin treatment. The only prior study of silibinin's effects on PCA cell adhesion were done with type I collagen, showing inhibited adhesion of PC-3 cells to that ligand [7].

By immunostaining, prostatectomy tissue from silibinin-treated men did not differ in CD44v9 expression from that of untreated men. This lack of effect has two good explanations. First, the treatment was only for 2-4 weeks, minimizing the opportunity for the agent to alter CD44 expression in the tumor. Second, samples from this cohort of men are being tested to determine the tissue absorption into the prostate. Despite the high serum levels achieved, we have not confirmed reliable tissue penetration.

Silibinin's suppression of CD44 promoter activity which diminishes total CD44 RNA and protein is probably indirect. Factors that regulate CD44 expression by binding its consensus overexpressed in androgen-independent cells such as PC-3, primary PCA, and PCa metastatic to other tissues [1-3]. Interference against CD44v7-10 reduced invasion index by 69% compared to untreated control cells [3]. Moreover, PCA loses the splicing ability to produce the standard isoform expressed in benign prostate that constitutes most of total CD44 [3-6] along with moderate levels of CD44v3-10 variant [6]. In PC-3 prostate tumor, CD44s transfection reduced invasion in vitro [20] and its tumorigenicity in mouse xenografts [21]. Silibinin's ability to reduce pro-invasive CD44v7-10 undoubtedly contributes to its effects.

Figure 5. Western blot analysis of 25-200 µM silibinin-treated PC-3M cells using polyclonal anti-Egr-1. LNCaP and DU145 whole cell lysates are used as negative controls. Monomeric 55-kD and dimeric 110-kD cytoplasmic Egr-1 bands are seen, as well as a 75-kD band that had been described as specific to nuclear Egr-1 [19]. Below: β-actin is shown as a normalizer.

Below:
Silibinin suppresses CD44 expression

promoter include Egr-1 [13,22], epidermal growth factor (EGF) [23], activating protein-1 (AP-1) [24], and H-ras [25]. Early growth response (EGR) genes encode zinc finger DNA-binding nuclear transcription factors, control cell proliferation, and show divergent expression in various human tumors. In PCa, Egr-1 binds to the androgen receptor [26] with important physiologic implications. One of us [23] demonstrated increased Egr-1, but not Egr-2 or EGR-α expression, in malignant prostate tissue as compared with weak expression in benign tissue. By in situ hybridization, the expression of Egr-1 was highest in tumors of Gleason score 8-10 than in those of lower Gleason score. Here we showed for the first time that the therapeutically relevant 100 µM dose of silibinin suppresses the high level of Egr-1 in prostate cancer (PCa) cells, suggesting that Egr-1 modulates, at least in part, the effects of silibinin on CD44.

Our findings are not meant to imply that Egr-1 is the sole mediator of silibinin’s effects on CD44. Silibinin was reported to act on the MAP kinase pathway [11]. We have shown that MEK and p38 components of the MAP kinase pathway are functionally important for PCa cell expression of CD44 as well as possibly in its splicing [27]. Silibinin also inhibits the PI3K-Akt signaling pathway [11]. Further, it is likely that Egr-1, by binding to GC-rich motifs of other genes, exerts pro-growth effects relevant to PCa that are not dependent on CD44. These include activation of ICAM-1/CD54 [13], which is relevant to PCa growth [28], repression of Fas/CD95 gene [13], required for apoptosis, and repression of transforming growth factor-β Type II receptor, shutting off a growth-inhibitory pathway [29].

In conclusion, silibinin exerts functional effects on CD44 through the CD44 promoter, leading to reduced CD44 total and CD44v7-10 expression. These changes are accompanied by altered adhesion to known extracellular matrix substrates of CD44.

Acknowledgement

This work was supported by Department of Defense Prostate Cancer Research Program, Grant PC060671 to K.A.I. We thank Dr. Steve K. Nordeen for advice.

References

Silibinin suppresses CD44 expression


